Skip to content

TRAVERE THERAPEUTICS, INC.: 10-K/A filed 2013-09-16

What TRAVERE THERAPEUTICS, INC. reported in its annual report amendment filed 2013-09-16 (fiscal FY 2012): 24 published measures, 59 facts as tagged in accession 0001193805-13-001600.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2013-09-16
Fiscal period
fiscal FY 2012
Accession
0001193805-13-001600 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TRAVERE THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-12-312,391,265USD
At 2011-12-3119,570USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-12-31-3,407,815USD
At 2011-12-31-536,285USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-12-3111,388USD
At 2011-12-3110,053USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-30,343,856USD366
2011-03-11 to 2012-12-31-33,612,112USD662
2011-03-11 to 2011-12-31-3,268,256USD296

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-2,736,739USD366
2011-03-11 to 2012-12-31-3,522,486USD662
2011-03-11 to 2011-12-31-785,747USD296

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-24,774USD366
2011-03-11 to 2012-12-31-27,646USD662
2011-03-11 to 2011-12-31-2,872USD296

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-12-314,437,667USD366
2011-03-11 to 2012-12-315,246,339USD662
2011-03-11 to 2011-12-31808,672USD296

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,699,593USD366
2011-03-11 to 2012-12-311,712,465USD662
2011-03-11 to 2011-12-3112,872USD296

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-12-3123,790USD
At 2011-12-312,517USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-12-3116,012,850USD366
2011-03-11 to 2012-12-3117,737,817USD662
2011-03-11 to 2011-12-311,724,967USD296

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-12-3133,218USD
At 2011-12-3117,053USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-01-01 to 2012-12-31105,917USD366
2011-03-11 to 2012-12-31105,917USD662

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-12-315,799,080USD
At 2011-12-31555,855USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-12-311,023,320USD
At 2011-12-31340,134USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-01-01 to 2012-12-3130,257,017USD366
2011-03-11 to 2012-12-3133,520,713USD662
2011-03-11 to 2011-12-313,263,696USD296

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2012-01-01 to 2012-12-311,292,296USD366
2011-03-11 to 2012-12-311,356,108USD662
2011-03-11 to 2011-12-3163,812USD296

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-01-01 to 2012-12-31524,000USD366
2011-03-11 to 2012-12-31877,000USD662
2011-03-11 to 2011-12-31353,000USD296

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-12-318,952,905shares
At 2011-12-314,042,265shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-12-3130,203,402USD
At 2011-12-312,766,567USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-12-312,467,796USD
At 2011-12-31169,721USD

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-12-31124,885USD366
2011-03-11 to 2012-12-31125,240USD662
2011-03-11 to 2011-12-31355USD296

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2012-01-01 to 2012-12-31-1,906USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-12-313,475,703USD366
2011-03-11 to 2012-12-314,238,375USD662
2011-03-11 to 2011-12-31762,672USD296

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-12-31680,865USD366
2011-03-11 to 2012-12-311,020,999USD662
2011-03-11 to 2011-12-31340,134USD296

Inspect the source

Entity
TRAVERE THERAPEUTICS, INC. / CIK 0001438533
Captured
2026-09-20T09:03:46.664Z
SEC response SHA-256
b66a9ecfb78fb2c3fc29384fc9ee702340e57ee037364236a402186d866938b6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001438533.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))